Literature DB >> 17606024

Continuous positive airway pressure for the treatment of sleep apnea.

Susmita Chowdhuri1.   

Abstract

Continuous positive airway pressure (CPAP) has become the treatment of choice for obstructive sleep apnea syndrome. Successful therapy with CPAP depends greatly on individual patient acceptance and compliance. Current indications for CPAP, including those for mild obstructive sleep apnea, will need to be revisited when results from the longitudinal follow-up of the Wisconsin Cohort and the Sleep Heart Health Study are made available.

Entities:  

Mesh:

Year:  2007        PMID: 17606024     DOI: 10.1016/j.otc.2007.04.011

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  5 in total

1.  Development of the National Healthy Sleep Awareness Project Sleep Health Surveillance Questions.

Authors:  Timothy I Morgenthaler; Janet B Croft; Leslie C Dort; Lauren D Loeding; Janet M Mullington; Sherene M Thomas
Journal:  J Clin Sleep Med       Date:  2015-09-15       Impact factor: 4.062

2.  The impact of modified tongue base suspension on CPAP levels in patients with severe OSA.

Authors:  Murat Turhan; Asli Bostanci; Mehmet Akdag
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-11       Impact factor: 2.503

3.  A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

Authors:  David H Winslow; Charles H Bowden; Karen P DiDonato; Pamela A McCullough
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

Review 4.  A systematic review of tongue base suspension techniques as an isolated procedure or combined with uvulopalatopharyngoplasty in obstructive sleep apnea.

Authors:  Asli Bostanci; Murat Turhan
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-27       Impact factor: 2.503

Review 5.  Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.

Authors:  William Timothy Garvey
Journal:  Expert Opin Drug Saf       Date:  2013-06-06       Impact factor: 4.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.